Topic: Altria

Altria sold its US rights for the IQOS heated tobacco system to Philip Morris for $2.7 billion. This move signals a shift away from liquid-based vapes toward tobacco-based "smokeless" products. The transition is seen as a way to protect the tobacco bond market and state tax revenues which were threatened by the rise of independent vaping companies.

A tobacco lawyer provided feedback on the "Vape Wars," clarifying the status of Juul's FDA application and the rise of synthetic nicotine as a way for small manufacturers to bypass current regulations. The discussion covers the Master Settlement Agreement and the influence of Big Tobacco on the industry.

Research into the S1 spike protein suggests it may be the primary driver of COVID-19 pathology. Some theories, previously discussed in early 2020, suggest that nicotine may interact with ACE2 receptors to prevent viral entry. While these claims were largely suppressed, tobacco giant Altria has recently expanded into medical inhalers and nicotine gum, signaling a potential shift toward therapeutic applications.

Altria is reportedly pivoting toward its new "IQOS" smokeless tobacco device after the systematic dismantling of the e-cigarette and Juul markets. The move is seen as an attempt to maintain tax revenue for states under the Master Settlement Agreement, which traditional vaping threatened. Critics predict the device will fail because it removes the social and sensory element of "blowing smoke" that users enjoy.

The FDA has cleared Philip Morris's IQOS heated tobacco device for sale in the United States. Unlike traditional vapes, the IQOS heats actual tobacco "heat sticks" without combustion, representing Big Tobacco's strategy to maintain its core business while moving away from traditional cigarettes.

Juul Labs CEO Kevin Burns resigned as the company suspended all advertising and lobbying efforts in the U.S. This coincides with Massachusetts Governor Charlie Baker declaring a four-month ban on all vaping products following a spike in lung illnesses. The industry shift occurs as major tobacco companies pivot toward new "heated tobacco" technologies.

Philip Morris International (PMI) and Altria ended merger discussions to focus on the U.S. launch of IQOS, a heated tobacco device already approved by the FDA. Critics suggest the recent vaping health scare was leveraged by the tobacco industry to destroy independent vape competitors. During a congressional hearing, Representative Rashida Tlaib questioned a vape advocate's motives, accusing her of being a conspiracy theorist.

Juul Labs, partially owned by Altria (formerly Philip Morris), is accused of utilizing Big Tobacco's historical playbook to secure market dominance through state-level legislation. The company employs hundreds of lobbyists to push for state laws that preempt local city ordinances, effectively making it harder for independent vape shops to operate. This strategy aims to position Juul as the primary FDA-approved option while eliminating smaller competitors.

Cynthia Cabrera, a veteran of the vapor trade association, clarified that the FDA has not yet approved any vaping products. By May 10, 2020, all products without a Pre-Market Tobacco Application (PMTA) will be considered illegal, a process costing roughly $1 million per flavor. Despite Altria's $13 billion investment for a 30% stake in Juul, they do not hold a board seat, and the industry faces a "regulatory shitstorm" fueled by media reports on lung illnesses.

Altria, the parent company of Philip Morris, has acquired a significant stake in the vape company Juul for $13 billion. A new study published in the New England Journal of Medicine claims e-cigarettes are twice as effective as traditional nicotine replacement therapies for quitting smoking. This marketing shift is compared to Edward Bernays' historical PR campaigns for the tobacco industry, rebranding "Big Tobacco" as "Big Nick."